Business
Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025
Expands senior leadership team and board of directors to support next phase of growthROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, “We are pleased with our revenue performance in the second quart
About this update from Milestone Scientific, Inc.
[{"type":"image","alt":"Milestone Scientific, Inc.","displaySize":"","headline":null,"caption":"Milestone Scientific, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":65,"url":"https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/exjbRkdU8va83bSGZUweuQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/2153125b7314814c812953238fb1ca11","width":300,"height":65}},"lazy":false},{"type":"text","content":"Expands senior leadership team and board of directors to support next phase of growth","length":85,"tagName":"p"},{"type":"text","content":"ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025.","length":305,"tagName":"p"},{"type":"text","content":"Neal Goldman, Chairman of the Board, stated, “We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management. Equally important, we have significantly strengthened our leadership and governance to support the next phase of accelerated growth — beginning with the appointment of Eric Hines as our new CEO. Eric brings exceptional experience leading successful organizations and driving operational excellence, and we are confident in his ability to guide Milestone through its next chapter. In addition, Jason Papes has joined as Senior Vice President, Global Head of Sales and Marketing, bringing a proven track record in building and executing global sales strategies. We also welcomed a new member to our Board of Directors — Shanth Thiyagalingam, an accomplished medtech executive with over 20 years of global leadership in commercial growth, product innovation, and reimbursement strategy. Together, these appointments significantly enhance our capabilities as we execute our growth strategy across both the medical and dental segments.”","...